Men at greater risk of developing prostate cancer when a brother has the disease

September 12, 2003

PHILADELPHIA (Sept. 11, 2003)-- It has been well-established that the risk of prostate cancer is increased among men who have a first-degree relative (father, son, brother) with the disease, but new research shows the risk is greatly increased for men who have a brother with prostate cancer. The meta-analysis research led by Deborah Watkins Bruner, Ph.D., at Fox Chase Cancer Center in Philadelphia, Pa., will be published online Friday, Sept. 12, 2003, in the International Journal of Cancer.

"This study is the first to report a statistically higher risk associated with having a brother with prostate cancer than having an affected father," said Bruner.

Bruner, director of the Prostate Cancer Risk Assessment Program at Fox Chase, and her colleagues conducted a systematic review and meta-analysis of the current literature, using 23 of 332 published studies that met meticulous criteria.

The results confirmed an increased risk of prostate cancer for men with a family history of the disease, but the meta-analysis revealed a 2.9 fold increased risk when the affected relative was a brother. The risk increased 1.8 fold when the affected relative was a second-degree family member (a grandfather or uncle), and 2.1 fold when the relative with prostate cancer was a father.

"Unlike the maternal-child pattern that we see with inherited breast cancers, a brother with prostate cancer was associated with a significantly increased risk of the disease compared to a father or any other relative with the disease," explained Bruner. "This may suggest that the risk may be related to shared environmental factors such as dietary exposures or age of onset of disease, which might reveal a stronger genetic risk."

Bruner said this is another crucial step to better identify who is at risk of developing prostate cancer. "The ultimate goal is to reduce unnecessary screenings and biopsies by identifying at-risk populations and better tailor prostate cancer screening for those men." Bruner concluded by saying more research into patterns of inherited prostate cancer risk is needed. "We need to assess the risk of disease associated with younger age [less than 65 or 70 years] of onset, dietary habits and lifestyle behaviors that may interact with inherited genes to increase prostate cancer risk."
-end-
For more information about the Prostate Cancer Risk Assessment Program at Fox Chase Cancer Center call 215-728-7041. Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Article: "Relative Risk of Prostate Cancer for Men with Affected Relatives: Systematic Review and Meta-Analysis." Deborah Watkins Bruner, Ph.D., Dirk Moore, Ph.D., Alicia Parlanti, M.S., Joanne Dorgan, Ph.D., Paul Engstrom, M.D.; International Journal of Cancer. www3.interscience.wiley.com/cgi-bin/jissue/76502439

Fox Chase Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.